Discounts Help Prompt UK’s NICE Turnaround on Dupixent and Ocrevus
After initially saying no, the UK health technology appraisal body, NICE, has recommended for use on the National Health Service Sanofi/Regeneron’s Dupixent and Roche’s Ocrevus. Confidential discounts helped convince NICE.
You may also be interested in...
Health technology assessment body NICE has changed its mind about the use of Ocrevus for treating primary progressive multiple sclerosis after Roche offered a lower price for the drug.
Roche is calling for HTA body NICE to have greater flexibility on indication-based pricing.
The UK's National Institute for Health and Care Excellence rejected Roche's ocrelizumab for provision to adults with primary progressive multiple sclerosis due to cost grounds and efficacy uncertainties - but observers expect a compromise to be eventually struck.